Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Big volume and upticking premarket.
May be one to watch.
Scheffler Dechambeau Spieth Nieman Finau 272
Scheffler Dechambue Morikawa Koepka Aberg 273
Ok ill go with Spieth instead of Clark.
Thanks
Scheffler An Aberg Clark Koepka 278
Adding
Scheffler Spieth Koepka Thomas D Johnson 283
Scheffler Schauffle Thomas Zalatoris Spieth 273
Nice volume this morning.
Kerplunk!
adding a few today.
William Alessi
Chief Executive Officer
Alpha Modus Corp
20311 Chartwell Center Drive | Suite 1469 | Cornelius, NC 28031
+1 (704) 790-9799 | mobile\
Hello. Attached are 2 company profiles cyap and xcpl I recently took a controlling stake in. A 1934 Act reporting Pink. And an alternative reporting Pink. Let me know if you have an interest in discussing either as I am exploring opportunities for both
balessi@alphamodus.com
this is the controlling shareholder.
Pm me your email and I can forward it to you.
i got an email from the controlling shareholder.
not sure if this is the new ceo or not.
.0002 x .0003
Rahm Koepka Hatton Fowler Fleetwood 280
Scheffler Koepka Day Schauffele Mickelson 272
United American Petroleum Corp. (Ticker: UAPC) Appoints Eddy Mansfield as President and Acquires Mansfield Productions, Inc.
9:02 am ET June 6, 2023 (Accesswire) Print
ORLANDO, FL / ACCESSWIRE / June 6, 2023 / United American Petroleum Corp. (OTC PINK:UAPC) is pleased to announce it has acquired Mansfield Productions, Inc. as a wholly owned subsidiary and appointed producer and entrepreneur, Eddy Mans- field, as the new President of UAPC.
Eddy Mansfield, a former two-sport professional athlete and now award-winning producer of television programming, has produced television programming for twenty years and engages the services of experienced, award-winning professionals in the television industry to ensure nothing less than the best quality television programming. Eddy has been featured on ABC's 20/20, CBS Morning News, TBS, Sports Illustrated, Los Angeles Times, New York Post, CBC, People, ESPN, Vice, and Texas Hot Country Magazine.
Moving forward, Eddy's primary goal remains that of producing high-quality television series, commercials and infomercials, with a focus on cutting edge, highly marketable content. Mansfield Productions, Inc. expects to continue pre-production or production on its 2023 slate including Nationally syndicated weekly radio/podcast Mouthing Off!, Smoke & Mirrors hosted by the star of American Truckers Robb Mariani, The World's Greatest Honky Tonk, Texas Hot Country, VanNation, Chokehold hosted by RVD, Fugitive Files, Stories Behind The Lyrics, Christmas Songs & The Stories Behind Them, and Octane Mania. We believe all projects will have network or syndication deals. Other projects include Chokehold The Movie.
About Mansfield Productions, Inc.
Mansfield Productions Inc. is engaged in the business of developing and producing television programming; more specifically, reality, sports, infomercials, and family-friendly series. The executive management team, headed by Eddy Mansfield and now award-winning producer of television programming, makes possible the pursuit of development, production, and marketing strategies which drive revenue streams and cash flow while building asset value, and ultimately, enhance shareholder value. Mansfield Productions will continue to utilize long-standing relationships with the creative community on both coasts and working with well-known talent, celebrities, and sports figures in its productions.
About UAPC
UAPC's mission is to acquire operating companies and assist small-business entrepreneurs in their growth and profitability. Through owning majority stakes in its subsidiary companies UAPC seeks to maximize the value of assets and continue with a mindset of growth and building shareholders' value.
Forward-Looking Statements. This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as "expect," "expectation," "believe," "anticipate," "may," "could," "intend," "belief," "plan," "estimate," "target," "predict," "likely," "seek," "project," "model," "ongoing," "will," "should," "forecast," "outlook" or similar terminology. These statements are based on and reflect our current expectations, estimates, assumptions and/ or projections as well as our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements are neither predictions nor guarantees of future events, circumstances or performance and are inherently subject to known and unknown risks, uncertainties and assumptions that could cause our actual results to differ materially from those indicated by those statements. There can be no assurance that our expectations, estimates, assumptions and/or projections, including with respect to the future earnings and performance or capital structure of United American Petroleum Corp. (UAPC).
Contact:
Edward Spade / CEO
www.UAPCstock.com/contact
321-578-7644
SOURCE: United American Petroleum Corp.
View source version on accesswire.com:
https://www.accesswire.com/759036/United-American-Petroleum-Corp-Ticker-UAPC-Appoints-Eddy-Mansfield-as-President-and-Acquires-Mansfield-Productions-Inc
comtex tracking
COMTEX_434437391/2457/2023-06-06T09:02:04
nice news.
Great idea
Rahm Koepka Finau D.Johnson J.Thomas 270
Of course you did.
Its over. Just be thankful you sold the rest you had before delisting.
Homa Morikawa Spieth Hovland Fleetwood 280
Rahm Homa Hovland Morikawa Spieth 276
$VYNT Looking for strategic alternative.
VYANT BIO ENGAGES LIFESCI CAPITAL TO EXPLORE STRATEGIC ALTERNATIVES
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value.
In addition, the Company announced that it is participating in BIO’s One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.
"The Company’s Board and Management believes that the Company has made tangible progress in its drug discovery strategy focused on the identification of new, disease modifying therapeutics to treat neurodevelopmental and neurodegenerative diseases," said Jay Roberts, Chief Executive Officer of Vyant Bio, “however, the Board and Management also believe that it would be a prudent time to contemplate strategic alternatives while continuing to execute on the current business plan.” There can be no assurance that this review process will result in any changes to the Company's current business plans or lead to any specific action or transaction. The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or the Company otherwise determines that further disclosure is appropriate.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics for treating the debilitating neurodevelopmental and neurodegenerative disorders for which there are no current therapies. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and familial Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to patients. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.
For more information, please visit or follow Vyant Bio at:
Internet: http://www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, and potential for our services, future revenue or growth in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapt to the global coronavirus pandemic, raise capital to meet our liquidity needs, successfully execute strategic alternatives that enhance shareholder value, and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Investor Contact:
Vyant Bio, Inc.
Andrew LaFrence, Chief Financial Officer
Email: Andrew.LaFrence@VyantBio.com
https://ir.vyantbio.com/news-events/press-releases/detail/1318/vyant-bio-engages-lifesci-capital-to-explore-strategic
$VYNT Looking for strategic alternative.
VYANT BIO ENGAGES LIFESCI CAPITAL TO EXPLORE STRATEGIC ALTERNATIVES
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value.
In addition, the Company announced that it is participating in BIO’s One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.
"The Company’s Board and Management believes that the Company has made tangible progress in its drug discovery strategy focused on the identification of new, disease modifying therapeutics to treat neurodevelopmental and neurodegenerative diseases," said Jay Roberts, Chief Executive Officer of Vyant Bio, “however, the Board and Management also believe that it would be a prudent time to contemplate strategic alternatives while continuing to execute on the current business plan.” There can be no assurance that this review process will result in any changes to the Company's current business plans or lead to any specific action or transaction. The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or the Company otherwise determines that further disclosure is appropriate.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics for treating the debilitating neurodevelopmental and neurodegenerative disorders for which there are no current therapies. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and familial Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to patients. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.
For more information, please visit or follow Vyant Bio at:
Internet: http://www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, and potential for our services, future revenue or growth in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapt to the global coronavirus pandemic, raise capital to meet our liquidity needs, successfully execute strategic alternatives that enhance shareholder value, and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Investor Contact:
Vyant Bio, Inc.
Andrew LaFrence, Chief Financial Officer
Email: Andrew.LaFrence@VyantBio.com
https://ir.vyantbio.com/news-events/press-releases/detail/1318/vyant-bio-engages-lifesci-capital-to-explore-strategic
$YOLO 3.45
Cannabis ETF
On Radar!
$YOLO 3.45
Cannabis ETF
On Radar!
$AAZ.v $AZURF
Due Diligence.
Website
http://azincourtenergy.com
Projects http://azincourtenergy.com/projects/east-…
Investors http://azincourtenergy.com/investor/prese…
About http://azincourtenergy.com/company/about-…
$AAZ.v $AZURF
Due Diligence.
Website
http://azincourtenergy.com
Projects http://azincourtenergy.com/projects/east-…
Investors http://azincourtenergy.com/investor/prese…
About http://azincourtenergy.com/company/about-…
$AAZ.v $AZURF
Due Diligence.
Website
http://azincourtenergy.com
Projects http://azincourtenergy.com/projects/east-…
Investors http://azincourtenergy.com/investor/prese…
About http://azincourtenergy.com/company/about-…
$AAZ.v $AZURF
Due Diligence.
Website
http://azincourtenergy.com
Projects http://azincourtenergy.com/projects/east-…
Investors http://azincourtenergy.com/investor/prese…
About http://azincourtenergy.com/company/about-…]
$AAZ.v $AZURF
Due Diligence.
Website
http://azincourtenergy.com
Projects http://azincourtenergy.com/projects/east-…
Investors http://azincourtenergy.com/investor/prese…
About http://azincourtenergy.com/company/about-…
lotto play.
Top 10 Holdings
Company YTD Return
(as of 02/15/2023) % of Assets
AdvisorShares Pure US Cannabis ETF +0.14% 30.76%
Jazz Pharmaceuticals PLC -6.21% 11.32%
* Village Farms International Inc -18.66% 10.31%
* Tilray Brands Inc +14.87% 7.52%
Innovative Industrial Properties Inc Registered Shs -10.68% 5.73%
GrowGeneration Corp +26.79% 4.53%
* High Tide Inc -4.55% 3.21%
* Canopy Growth Corp +5.19% 3.14%
* OrganiGram Holdings Inc +5.25% 3.01%
$YOLO
Cannabis ETF
On Radar!